{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:52:53Z","timestamp":1793368373630,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jval.2022.11.017","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:55:43Z","timestamp":1670547343000},"page":"465-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Shannon","family":"Cope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Borrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Branchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kupas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jval.2022.11.017_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Moher","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jval.2022.11.017_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154870","article-title":"Review of the reporting of survival analyses within randomised controlled trials and the implications for meta-analysis","volume":"11","author":"Batson","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"17","key":"10.1016\/j.jval.2022.11.017_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116774","article-title":"Statistical inference methods for two crossing survival curves: a comparison of methods","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"3-4","key":"10.1016\/j.jval.2022.11.017_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.jval.2022.11.017_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jrsm.1405","article-title":"Multivariate network meta-analysis of survival function parameters","volume":"11","author":"Cope","year":"2020","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.jval.2022.11.017_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jrsm.1253","article-title":"Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models","volume":"8","author":"Freeman","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2022.11.017_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jclinepi.2020.05.010","article-title":"Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base","volume":"124","author":"Freeman","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2022.11.017_bib11","article-title":"PNS92 a targeted review of indirect treatment comparison synthesis methods that do not rely on the proportional hazard assumption","volume":"24","author":"Cope","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-12-152","article-title":"Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes","volume":"12","author":"Jansen","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12885-019-5569-5","article-title":"Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: A systematic review and network meta-analysis","volume":"19","author":"Vickers","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13643-019-0984-x","article-title":"Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas","volume":"8","author":"Petit","year":"2019","journal-title":"Syst Rev"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-019-5507-6","volume":"19","author":"Connock","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jval.2022.11.017_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jval.2022.11.017_bib17","series-title":"The BUGS Book","author":"Lunn","year":"2013"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jval.2014.10.006","article-title":"Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints","volume":"18","author":"Owen","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.11.017_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"suppl 2","key":"10.1016\/j.jval.2022.11.017_bib20","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/j.jval.2020.08.420","article-title":"PCN283 extending multivariate network meta-analysis of survival function parameters to fractional polynomials","volume":"23","author":"Chan","year":"2020","journal-title":"Value Health"},{"issue":"15","key":"10.1016\/j.jval.2022.11.017_bib21","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parameteric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"issue":"21","key":"10.1016\/j.jval.2022.11.017_bib22","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/sim.6556","article-title":"Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data","volume":"34","author":"Wei","year":"2015","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jval.2022.11.017_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pst.1700","article-title":"Bias and precision of measures of survival gain from right-censored data","volume":"14","author":"Lamb","year":"2015","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jval.2022.11.017_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12874-016-0137-z","article-title":"Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis","volume":"16","author":"Lueza","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.jval.2022.11.017_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184423","article-title":"Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma","volume":"12","author":"Amzal","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jval.2022.11.017_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22060","article-title":"Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation","volume":"22","author":"Edwards","year":"2018","journal-title":"Health Technol Assess"},{"issue":"29","key":"10.1016\/j.jval.2022.11.017_bib27","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2217\/fon-2017-0268","article-title":"Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety","volume":"13","author":"El Rassy","year":"2017","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.jval.2022.11.017_bib28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/cancers12061673","article-title":"Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"12","author":"Elaidi","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jgo.2018.05.010","article-title":"Treatment of metastatic renal cell carcinoma in older patients: a network meta-analysis","volume":"10","author":"Hale","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jval.2022.11.017_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024691","article-title":"Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis","volume":"9","author":"Karner","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2022.11.017_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.critrevonc.2018.10.004","article-title":"Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: systematic review and indirect treatment comparison","volume":"139","author":"Porta","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.jval.2022.11.017_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212899","article-title":"Indirect treatment comparisons including network meta-analysis: lenvatinib plus everolimus for the second-line treatment of advanced\/metastatic renal cell carcinoma","volume":"14","author":"Tremblay","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jval.2022.11.017_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155389","article-title":"Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma","volume":"11","author":"Wiecek","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jval.2022.11.017_bib37","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"14","key":"10.1016\/j.jval.2022.11.017_bib38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jval.2022.11.017_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.jval.2022.11.017_bib40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jval.2022.11.017_bib41","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jval.2022.11.017_bib42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.jval.2022.11.017_bib43","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426","volume":"38","author":"Plimack","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2022.11.017_bib44","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2022.11.017_bib45","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jval.2022.11.017_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.jval.2022.11.017_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc B"},{"key":"10.1016\/j.jval.2022.11.017_bib48","series-title":"Applied Survival Analysis","author":"Hosmer","year":"2008"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.jval.2022.11.017_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.jval.2022.11.017_bib51","author":"Latimer"},{"issue":"4","key":"10.1016\/j.jval.2022.11.017_bib52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J\u00a0R Stat Soc B"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2288-13-147","article-title":"Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making","volume":"13","author":"Cope","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.jval.2022.11.017_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jval.2022.11.017_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/00031305.1998.10480531","article-title":"Nonlocal behavior in polynomial regressions","volume":"52","author":"Magee","year":"1998","journal-title":"Am Stat"},{"issue":"7","key":"10.1016\/j.jval.2022.11.017_bib59","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0272989X19873661","article-title":"Generalized linear models for flexible parametric modeling of the hazard function","volume":"39","author":"Kearns","year":"2019","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2022.11.017_bib60","author":"Rutherford"},{"key":"10.1016\/j.jval.2022.11.017_bib61","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et\u00a0al. Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). 661P. Presented at: European Society for Medical Oncology, September 16-21, 2021; Virtual Congress.","DOI":"10.1016\/j.annonc.2021.08.057"},{"issue":"3","key":"10.1016\/j.jval.2022.11.017_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40273-020-00989-1","article-title":"What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell carcinoma","volume":"39","author":"Klijn","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2022.11.017_bib63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/09622802211070253","article-title":"Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: application to a melanoma network","volume":"31","author":"Freeman","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jval.2022.11.017_bib64","author":"Dias"},{"issue":"6","key":"10.1016\/j.jval.2022.11.017_bib65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2022.11.017_bib67","author":"Dias"},{"key":"10.1016\/j.jval.2022.11.017_bib68","author":"Woods"},{"issue":"7","key":"10.1016\/j.jval.2022.11.017_bib69","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jval.2020.03.010","article-title":"Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis","volume":"23","author":"Wiksten","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.11.017_bib70","series-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"10.1016\/j.jval.2022.11.017_bib71","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","article-title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"65","author":"Ruiz-Morales","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jval.2022.11.017_bib72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-019-00853-x","article-title":"How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime mean survival and cost effectiveness","volume":"38","author":"Kearns","year":"2020","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:24Z","timestamp":1761096744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1098301522047490"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.017","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}